KBC Securities - BIOTALYS NV (BTLS) Morning Notes : BTLS BB

Report

KBC Securities

Thomas Vranken

Morning Notes : BTLS BB

: BTLS BB

17/09/2024 1 EN

Underlying

BIOTALYS NV

See profile

BE0974386188 Euronext Brussels Belgium

Provider

KBC Securities

We are a financial services provider for several types of professional clients, each with distinct needs.

See profile

Analysts

Thomas Vranken

Other Reports on these Companies

KBC Securities

Morning Notes : GIMB BB, UCB BB, MAAT FP, BTLS BB

: GIMB BB, UCB BB, MAAT FP, BTLS BB

March 19, 2025 March 19, 2025 1 EN

KBC Securities

Biotalys FIRST LOOK: Good financial management; but focus could be on operational hiccups

In FY24, Biotalys optimized its capital resources, achieving a significant reduction in operating expenses while strengthening its balance sheet through a successful private placement. Looking ahead, they plan to further advance their product portfolio and develop novel modes of action, as well as expand options to scale and produce their biobased solutions. So we saw in FY24 good financial management - runway reaching into May-26 - but focus could be on some operational hiccups.

March 19, 2025 March 19, 2025 1 EN

KBC Securities

Morning Notes : AGFB BB, DIE BB, DECB BB, KIN BB, UCB BB, BTLS BB

: AGFB BB, DIE BB, DECB BB, KIN BB, UCB BB, BTLS BB

March 11, 2025 March 11, 2025 1 EN

Materialise Medical segment continues to lead the way

Materialise indicated that - amidst the current macro-economic and geo-political turbulence - they managed to grow their 1Q25 revenue 4.3% y/y. Materialise's Medical segment continued to lead the way with 18.7% revenue growth y/y. Uncertain market conditions continued to weigh on its Materialise Manufacturing and Materialise Software segments. On the other hand, we welcome that Materialise significantly increased the deferred revenue carried on its balance sheet. Although overall 1Q25 profitability declined y/y Materialise indicated they continue to realize operational efficiencies compared to...

20h / 45m 20h / 45m 1 EN

Jacob Mekhael ... (+4)

Jacob Mekhael
Kristof Samoy
Lynn Hautekeete
Wim Hoste

Morning Notes : IMMO BB, RECT BB, EKOP BB, MAAT FP

: IMMO BB, RECT BB, EKOP BB, MAAT FP

22h / 30m 22h / 30m 1 EN

Jacob Mekhael

Jacob Mekhael

MaaT Pharma MaaT034 preclinical data at AACR shows potential in solid tumours

MaaT presented new preclinical data for MaaT034 (donor-independent co-cultured microbiome therapy) at the American Association for Cancer Research (AACR) conference, being held 25-30 April in Chicago. The results show the potential for microbiome therapies to improve responses in solid tumours when combined with immune checkpoint inhibitors. Results from a phase 2 investigator-initiated placebo-controlled trial of MaaT013 (microbiome therapy, enema formulation) in combination with checkpoint inhibitors Yervoy (anti-CTLA-4) and Opdivo (anti-PD1) in metastatic melanoma is due to report results i...

22h / 44m 22h / 44m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

Morning Notes : BTLS BB

We are a financial services provider for several types of professional clients, each with distinct needs.

Morning Notes : GIMB BB, UCB BB, MAAT FP, BTLS BB

Biotalys FIRST LOOK: Good financial management; but focus could be on operational hiccups

Morning Notes : AGFB BB, DIE BB, DECB BB, KIN BB, UCB BB, BTLS BB

Materialise Medical segment continues to lead the way

Morning Notes : IMMO BB, RECT BB, EKOP BB, MAAT FP

MaaT Pharma MaaT034 preclinical data at AACR shows potential in solid tumours

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe